Brief: Anavex Life Sciences Announces Acceptance Of Peer-Reviewed Manuscript
25/11/2024 12:41
Nov 25 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* ANAVEX LIFE SCIENCES ANNOUNCES ACCEPTANCE OF PEER-REVIEWED
MANUSCRIPT OF ORAL BLARCAMESINE PHASE IIB/III DATA IN A
REFERENCE ALZHEIMER’S DISEASE JOURNAL
Source text: ID:nGNX8CVmg0
Further company coverage: AVXL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board